-
DailyClout Makes Legislation Easy to Understand, Share and Act Upon
Join the CommunitySearch BillCam
-
LET'S SAVEDEMOCRACYTOGETHER
March 18, 2022
Melissa Blasek
New Hampshire House Session: Day 3
Dear DailyClout Community, Day 3, we passed the remainder of my priority bills. HB 1089, relative to unenforceability of non-compete contracts upon termination of an employee for vaccine mandate noncompliance. HB 1210, in my opinion, a weak solution to the employee mandate issue, but it’s the best I could get. …
March 17, 2022
Bannons War Room on Rumble
Dr. Wolf – Lack of Discernment in COVID-19 Vaccine Dosing
In this video, Dr. Wolf voices concerns regarding the spiked proteins present in the COVID-19 vaccines. She explains the lack of discernment in doses of the vaccine. Internal documents show “recommended” doses for young children in comparison to adults as frighteningly similar. Watch the video for Dr. Wolf’s explanation of …
March 17, 2022
Melissa Blasek
New Hampshire House Session: Day 1
Dear DailyClout Community, It was a great day one at the New Hampshire Statehouse in Concord, NH. Among many other successes of the day, these bills were passed through the House and head to the Senate: HB 1606, making the vaccine registry opt in. HB 1208, prohibiting a parent’s refusal …
March 17, 2022
Melissa Blasek
Republican Majority Defending Rights and Freedom in New Hampshire
Dear DailyClout Community, Here’s a wrap-up of what went on in the New Hampshire House today March 16 2022. Needless to say, the Republican majority was defending your rights and expanding freedom in NH. These bills passed: HB 1022, making ivermectin available via a standing order HB 1044, allowing direct …
March 17, 2022
Zoe Wilson
Comparisons Between Pfizer’s EUA, Pfizer’s Cumulative Analysis of Post-Authorization Adverse Event Reports, and New Studies Raises Several New Questions
There was a recent study that was published on January 25, 2022 with data compiled from December 2020 through August 2021. https://jamanetwork.com/journals/jama/fullarticle/2788346 There is a cross over in timeline between that new study and Pfizer’s Cumulative Analysis of Post-Authorization Adverse Event Reports, document 5.3.6. https://phmpt.org/wp-content/uploads/2021/11/5.3.6-postmarketing-experience.pdf Document 5.3.6 contains data from December 2020 …